Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide

Viral Immunology

Volumn 15, Issue 2, 2002, Pages 337-356

  Blomquist, Dania Vázquez ^a   Green, Philip ^b   Laidlaw, Stephen M ^b   Skinner, Michael A ^b   Borrow, Persephone ^c   Duarte, Carlos A ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c Churchill Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; FPTAB9LZ; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POLYPEPTIDE; VIRUS PROTEIN; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE; PEPTIDE FRAGMENT; TAB9;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; EXPRESSION VECTOR; FOWLPOX VIRUS; GENE EXPRESSION SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT; ANIMAL; CD8+ T LYMPHOCYTE; CELL LINE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG ADMINISTRATION ROUTE; GENE EXPRESSION; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; SPLEEN; VACCINATION;

ANIMALIA; AVIPOXVIRUS; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS; VECTORS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG ADMINISTRATION ROUTES; EPITOPES; EPITOPES, T-LYMPHOCYTE; FOWLPOX VIRUS; GENE EXPRESSION; GENETIC VECTORS; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INJECTIONS, INTRAVENOUS; MICE; PEPTIDE FRAGMENTS; PEPTIDES; RECOMBINATION, GENETIC; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINIA VIRUS;

EID: 0036048537     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/08828240260066260     Document Type: Article

References (86)

1. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)
2. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120
3. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
4. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
5. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
6. Multivalent minigene vaccines against infectious disease
7. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
8. Reduction of simian-human immunodeficiency virus 89.6p viremia in rhesus monkeys by recombinant modified vaccinia virus ankara vaccination
9. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
10. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
11. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV (mac251): Dependence on route of challenge exposure
12. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1envelope glycoprotein
13. Analysis of the fowlpox virus gene encoding the 4b core polypeptide and demonstration that it possesses efficient promoter sequences
14. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
15. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
16. The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is nonessential and highly immunogenic
17. Immunisation with canarypox virus expressing rabies glycoprotein
18. Tandem repeated sequences within the terminal region of the fowlpox virus genome
19. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
20. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
21. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1
22. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunzations for HIV-1 envelope presentation
23. Vaccinia virus expression vector: Coexpression of β-galactosidase provides visual screening of recombinant virus plaques
24. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
25. H-2Dd exploits a four residue peptide binding motif
26. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein
27. Structure of vaccinia virus early promoters
28. Recombinant vaccinia viruses and the development of immunization strategies using influenza virus
29. Multi-epitope polypeptide of HIV-1 envelope induces neutralizing monoclonal antibodies against the V3 loop
30. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type I envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus
31. Induction of humoral and cellular immune responses in mice by a recombinant fowlpox virus expressing the E2 protein of bovine viral diarrhea virus
32. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
33. + cytotoxic T lymphocyte responses in seronegative volunteers
34. A successful eradication campaign. Global eradication of smallpox
35. Human safetly and immunogenicity of a canrypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
36. + nef-specific cytotoxic T cells in vaccinated macaques
37. Challenge of chimpanzees immunized with a recombinant canarypox-HIV- 1 virus
38. The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA 720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates
39. + T cell response against a V3 loop multi-epitope polypeptide (TAB 13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVATAB): A comparison of humoral and cellular immune responses with vaccinia virus Western Reserve (WR) vector
40. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
41. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
42. Immunogenicites of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
43. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
44. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
45. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice
46. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
47. Effect of different adjuvants and immunomodulators on the humoral immune response of rabbits and mice against HIV-1 derived multi-epitope polypeptides
48. General method for the rapid synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids
49. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
50. + T cell depletion in simian immunodeficiency virus-infected macaques
51. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
52. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
53. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
54. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
55. Vaccinia virus: A selectable eukaryotic cloning and expression vector
56. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
57. Attenuierung von virulentem huhnerpockenvirus in zellkulturen und eigenschaften des attenuierten virus
58. Broadly reactive antibodies against V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1)
59. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
60. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
61. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
62. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus
63. Applications of pox virus vectors to vaccination: An update
64. Safe and effective poxvirus vectors - NYVAC and ALVAC
65. The global impact of HIV/AIDS
66. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F)
67. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
68. The prime-boost strategy: Exciting prospects for improved vaccination
69. A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9
70. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
71. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
72. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
73. Molecular cloning
74. + lymphocytes
75. Vaccines against intracellular infections requiring cellular immunity
76. Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160
77. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells
78. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes
79. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule
80. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells
81. Fowlpox virus as a vector in non-avian species
82. Efficacy evaluation of prime-boost protocol: Canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats
83. + cytotoxic T cells: Implications for vaccine development
84. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers
85. + cytotoxic T-cell epitopes
86. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses